The upregulation of immunogenic peptides such as PD-L1 and MHC class I in intrahepatic CCA cell lines after trametinib exposure [146] suggests that these peptides may be potential targets for immune checkpoint therapies. The gene discussed is CD274; the disease is cholangiocarcinoma.